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The commensal microbiota modulates immunological and metabolic aspects of the intesti-
nal mucosa contributing to development of human gut diseases including inflammatory
bowel disease. The host/microbiota interaction often referred to as a crosstalk, mainly
focuses on the effect of the microbiota on the host neglecting effects that the host could
elicit on the commensals. Colonic microenvironments from three human healthy con-
trols (obtained from the proximal and distal colon, both in resting conditions and after
immune – IL-15- and microbiota – LPS-in vitro challenges) were used to condition a stable
fecal population. Subsequent 16S rRNA gene-based analyses were performed to study the
effect induced by the host on the microbiota composition and function. Non-supervised
principal component analysis (PCA) showed that all microbiotas, which had been condi-
tioned with colonic microenvironments clustered together in terms of relative microbial
composition, suggesting that soluble factors were modulating a stable fecal population
independently from the treatment or the origin. Our findings confirmed that the host intesti-
nal microenvironment has the capacity to modulate the gut microbiota composition via yet
unidentified soluble factors. These findings indicate that an appropriate understanding of
the factors of the host mucosal microenvironment affecting microbiota composition and
function could improve therapeutic manipulation of the microbiota composition.
Keywords: host–microbiota interaction, molecular crosstalk, soluble mediators, microbial modulation, metage-
nomics
INTRODUCTION
The immune system of the gastrointestinal tract (GIT) is exposed
to a large amount of foreign but harmless antigens typically
derived from nutrients and commensal bacteria but sometimes
deleterious when derived from infectious bacteria or viruses. Nev-
ertheless, the GIT immune system is effective in discriminating
between maintaining immune tolerance against diet and/or com-
mensal derived antigens, and initiating immune responses against
harmful invading pathogens (1). IL-15 is one of the cytokine
of the innate immune response, regulating both T and natural
killer (NK) cell activation and proliferation (2). The commen-
sal microbiota plays a central role in modulating the outcome of
immune responses in the GIT keeping immune homeostasis in
health (3). Indeed, germ-free animals have an immature immune
system and can develop inflammation, which is reversed once the
microbiota is conventionalized (4). The commensal microbiota
modulates several aspects of the host including the physiology
and/or its nutritional status. The microbiota is also related to
several diseases affecting the gut, like in inflammatory bowel dis-
eases (IBD), and also influences diseases in distant organs (5–8).
On turn, chronic gut inflammation such as happens in IBD is
a risk factor for colorectal cancer. This is apparently a conse-
quence of a high and persistent inflammation at the mucosa
levels (9).
Gastrointestinal tract microbiota modulation is a promising
area of research aiming at an impact in the clinics for patients
suffering from GIT diseases, such as IBD. Traditional approaches
included the use of antibiotics and/or pre/pro/synbiotic combi-
nations which, although effective to some extent, usually have
short-term success (10). Novel approaches are trying to modu-
late the abnormal microbiota composition in different ways, such
as fecal transplants, which have been effective in treating recurrent
Clostridium difficile infections and other extra-intestinal diseases
(11–13). However, there is variability in the results as the treat-
ments are not effective in all patients, partially due to the stability
of the human microbiota (14, 15). Indeed, the possibility exists
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that the host exerts some selective pressure on the microbiota
modulating its composition.
The GIT human microbiota is not stable as it increases its con-
tent [up to 1012 bacteria per gram of colon content (16)], and
changes its composition and metabolism through the GIT tract,
likely revealing different adaptations to different GIT sections (17–
19). The host–microbiota crosstalk is mediated, at least partially,
through bacteria-derived soluble factors and not necessarily via
direct cell interaction (20–22) and the microbiota composition can
indeed be altered during inflammation (23). Nevertheless, there
are few studies regarding the way in which the local gut microen-
vironment influences the microbiota in terms of composition and
functionality.
In the human large bowel, the proximal (right) and distal
(left) sections have different embryological origin, blood sup-
ply/vascularization, lymphatic drainage, and enzymatic activities
(24, 25). Epithelial cells from these compartments have different
genetic and epigenetic profiles coupled with different antibody
secreting cells; thus, immune differences between the proximal
and the distal colon could provide different niches for commensal
microorganisms (26–28). Besides, similar to how different patients
have different immune response thresholds to external challenges,
the proximal and the distal colon may also have different response
thresholds to external immune challenges (2, 23). Therefore, we
undertook studies of host–microbiota crosstalk in proximal and
distal areas of the colonic both in resting conditions and after
immune challenges, which could disrupt immune homeostasis
affecting the local microenvironment.
Here, we hypothesize that the host can modulate the micro-
biota composition and metabolic activities. Colonic microenvi-
ronments from the human proximal and distal colon (both in
resting conditions and after immune challenges) were, therefore,
used to condition a stable fecal slurry population. Our results
proved that the host exerted a selectively pressure on the micro-
biota composition via host-derived soluble factors. Main results
are discussed below.
MATERIALS AND METHODS
ETHICAL STATEMENT
The study was approved by the Bioethics Committee from Hos-
pital Clínico Universitario from Valladolid, Spain in compliance
with the Declaration of Helsinki. All patients provided informed
consent on entry to the study.
HOST FACTORS
Biological samples
Colonic biopsies were obtained at colonoscopy from three healthy
female controls (ages 40, 57, and 66 years old) who had been
referred for colorectal cancer screening and were macroscopically
and histologically normal.
Paired samples were collected from the distal (left) and prox-
imal (right) human colon (total of four biopsies from each area)
in ice chilled PBS and processed within an hour. One biopsy from
each compartment (proximal/distal) was used to assess the profile
of intraepithelial lymphocytes (IEL) as described below while the
other three biopsies were cultured in 1 ml of complete medium
[Dutch modified RPMI 1640 (Sigma-Aldrich, Dorset, UK) con-
taining 2 mM l-glutamine (Sigma-Aldrich) and 10% fetal calf
serum (TCS cellworks, Buckingham, UK)] for 24 h in 12 well
culture dishes and in the absence of antibiotics (1 biopsy/well)
(37°C, 5% CO2) in basal conditions or challenged with IL-
15 (50 ng/ml, R&D) or LPS (Escherichia coli; 10 ng/ml Sigma).
After 24 h, media from biopsy culture were centrifuged, filtered
(0.2µm), and cell/bacterial-free supernatants collected and pre-
served at −80°C. Negative controls included parallel processing
(including 24 h incubation in culture dishes within the incubator
and subsequent centrifugation and cryopreservation) of complete
medium, which had not been conditioned with colonic samples.
Intraepithelial lymphocytes
Colonic biopsies were incubated for 1 h under gentle agitation
with 1 mM dithiothreitol (DTT) (Sigma-Aldrich) and 1 mM ethyl-
enediaminetetraacetic acid (EDTA) (Sigma-Aldrich) in complete
medium after which IEL were released into the medium and
collected by centrifugation, washed twice in PBS (Lonza, Braine-
l’Alleud, Belgium), and stained with fluorochrome-conjugated
antibodies.
Antibody staining and flow cytometry acquisition
For IEL subset characterization, monoclonal antibodies with the
following specificities and conjugations were used: CD45-PE-Cy7
(HI30), CD103-FITC (Ber-ACT8), CD3-APC (HIT3a), and Tγδ-
PE (B1) were purchased from Becton Dickinson while CD4-FITC
(13B8.2) and CD8-PE (B9.11) were purchased from Beckman
Coulter. Cells were labeled in PBS containing 1 mM EDTA and
0.02% sodium azide (FACS buffer). Labeling was performed on
ice and in the dark for 20′. Cells were washed twice in FACS buffer,
fixed with 1% paraformaldehyde in 0.85% saline, and stored at 4°C
prior to acquisition on a Beckman Coulter FC500 flow cytome-
ter (within 48 h). Appropriate isotype-matched control antibodies
were purchased from the same manufacturers. IEL were identi-
fied as CD45+CD103+ and were further characterized as T-cells
(CD3+) [both classical T-cells (CD3+TCRγδ−) and Tγδ cells
(CD3+TCRγδ+)] or NK-like cells (CD3−). Within T-cells CD4+
and CD8+subsets were further identified.
Culture supernatants
Cell-free culture supernatants were analyzed by using a Flow
Cytomix Multiple Analyte Detection (EBioscience) on a BD FAC-
SCanto II flow cytometer (BD) following the manufacturer’s
instructions, for the concentration of interferon (IFN)γ [detection
limit (D.L.) 0.25 pg/ml]; interleukin (IL)-1β (D.L. 1.80 pg/ml); IL-
2 (D.L. 0.35 pg/ml); IL-4 (D.L. 1.22 pg/ml); IL-5 (D.L. 0.76 pg/ml);
IL-6 (D.L. 4.10 pg/ml); IL-9 (D.L. 1.17 pg/ml); IL-10 (D.L.
2.88 pg/ml); IL-12p70 (D.L. 0.1 pg/ml); IL-13 (D.L. 0.43 pg/ml);
IL-17A (D.L. 0.89 pg/ml); IL-22 (D.L. 3.98 pg/ml); IL-23 (D.L.
29.14 pg/ml); IL-27 (D.L. 0.79 pg/ml); leptin (D.L. 34.95 pg/ml),
and tumor necrosis factor α (TNF-α) (D.L. 3.10 pg/ml). IgA
content from each compartment was determined with radial
immunodiffusion kit (Kit IgA RID-ML, Binding Site, UK, D.L 8.5–
85 mg/l) following manufacturer’s instructions. All values below
D.L. were reported as being equal to that.
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MICROBIOTA EXPERIMENTS
Basal media
Cell-free culture supernatants from the proximal and distal colon,
both in resting conditions (basal) and after immune challenges
(LPS and IL-15), were subsequently used to explore their effect
on a stable fecal population via the fecal slurry model. For this
purpose, we used a basal media composed of 2 g/l peptone water
[Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA]
2 g/l yeast extract (BD), 0.1 g/l NaCl, 0.04 g/l K2HPO4, 0.04 g/l
KH2PO4, 0.01 g/l MgSO4, 0.01 g/l CaCl2.·2H2O, 2 g/l NaHCO3,
2.5 g/l l-Cysteine-HCl, 0.5 g/l bile salts, 2 ml/l Tween-80, 1 g/l ara-
binogalactan, 2 g/l pectin, 1 g/l xylan, 4 g/l starch, 0.4 g/l glucose,
and 0.4 g/l mucin type III (all purchased to Sigma-Aldrich). The
mixture was homogenized and autoclaved for 15 min at 121°C,
and the following components were added to the cooled media
after sterilization by filtration (0.20µm): 0.05 g/l bovine hemin
(Sigma-Aldrich) and 10µg/l vitamin K (Sigma-Aldrich). Before
use, the basal media was maintained overnight at 37°C in anaer-
obiosis (10% v/v H2, 10%CO2, and 80% N2) in an anaerobic
chamber Mac 500 (Don Whitley Scientific, West Yorkshire, UK).
Batch fecal slurry and sample points
The inoculum for the fecal slurry was prepared from the feces
of a healthy adult volunteer (woman, 26 years old), who had not
received antibiotics during the 6 months prior to the study. Feces
were diluted (10% w/v) in sterile 0.17M phosphate buffered saline
(pH 7) supplemented with 0.25% (w/v) cystein, and homogenized
using a Lab-Blender 400 stomacher (Seward Medical, London,
UK) for 2 min. Ten milliliters of the fecal homogenate were mixed
with 90 ml of the basal media, and the fecal population was allowed
to stabilize by an overnight incubation at 37°C in anaerobiosis.
Biopsy culture supernatants (500µl) were added to 2 ml of
the stabilized fecal slurry, and the mixes were incubated for 48 h
at 37°C, including three tubes in which the same volume of
un-conditioned media was added. Samples were collected by cen-
trifugation (10 min, 16,000× g, 4°C) at times 0 and 48 h. DNA
isolation was performed using the QIAampDNA stool Mini kit
(Qiagen, GmbH, Hilden, Germany) following the manufacturer
instructions.
16S rRNA gene profiling analysis
Partial 16S rRNA gene amplicons were obtained with primers Pro-
bio_Uni and/Probio_Rev (targeting the V3 and V4 region) by
PCR (29). The products were purified, and a sequence library
was prepared and sequenced in an Ion Torrent PGM system at
the GenProbio Ltd., facilities1, using the Ion Sequencing 200 kit
(Life Technologies, Thermo Fisher Scientific,Waltham, MA, USA).
After sequencing, the individual sequence reads were filtered by the
PGM software to remove low quality and polyclonal sequences.
Sequences matching the PGM 3′ adaptor were also automatically
trimmed. All PGM quality-approved, trimmed and filtered data
were exported as.sff files.
The.sff files were processed using QIIME 1.7.0 running on an
Ubuntu server (30). Sequences with a length between 150 and
1http://www.genprobio.com
200 bp and mean sequence quality score>25 were retained as part
of our quality control. In addition, the sequence was trimmed at
the first base if a low quality rolling 10 bp window was found. Pres-
ence of homopolymers >7 bp, and sequences with mismatched
primers were omitted. In order to calculate downstream diver-
sity measures (alpha and beta diversity indices, Unifrac analysis),
16S rRNA Operational Taxonomic Units (OTUs) were defined
at ≥97% sequence homology. Chimeric sequences were removed
using ChimeraSlayer. All reads were classified to the lowest pos-
sible taxonomic rank using QIIME and a reference dataset from
GreenGenes2 (version 13.5, May 2013). OTUs were assigned using
uclust (31) by using the script pick_de_novo_otus.py. The hier-
archical clustering based on population profiles of most com-
mon and abundant taxa was performed using UPGMA clustering
(Unweighted Pair Group Method with Arithmetic mean). This
resulted in a Newick formatted tree, which was obtained utilizing
the QIIME package. Alpha diversity was calculated through the
alpha_diversity.py script using different metrics (Chao, Observed
Species, Shannon and Simpson) to take into account the species
evenness and richness.
The OTU tables were collapsed at five taxonomic levels (Phy-
lum, Class, Order, Family, and Genus), exported in tab-delimited
text format and analyzed using STAMP v2.0.1 (32). For each
condition, the metagenomic profiles were evaluated at the dif-
ferent taxonomic levels. In each case, a non-supervised principal
component analysis (PCA) was conducted, after which samples
were classified in the different conditions: (i) absence or pres-
ence of biopsy supernatants in the fecal slurry and (ii) different
biopsy/culture conditions. STAMP allows data filtering and analy-
sis by the application of different statistical test’s and corrections.
Association of taxa to the different grouping variables were iden-
tified by running two-sided Welch’s tests on every pair of means
(two grouping variables) or ANOVA/Tukey Kramer (post hoc) tests
(more than two grouping variables). The false discovery rate cor-
rection [FDR, (33)] was finally applied in all cases and significant
differences in taxa were only considered below a p-value of 0.05
and a q-value below 0.2 (34).
Functional inference analysis
The functionality of the different metagenomes was predicted
using the software PICRUSt 1.0.03 (35). Briefly, this software
allows the prediction of functional KEGG pathway abundances
from the 16S rDNA reads. First, a collection of closed reference
OTUs was obtained from the filtered reads using QIIME v1.7.0
(30) by querying the data against the GreenGenes database2 (ver-
sion 13.5, May 2013). Reverse strand matching was enabled during
the query and OTUs were picked at a 97 percent identity. A BIOM-
formatted table (Biological Observation Matrix) was obtained
with the pick_closed_reference_otus.py script. This table, contain-
ing the relative abundances of the different reference OTUs in all
the metagenomes, was normalized by the predicted 16S rDNA
copy number with the script normalize_by_copy_number.py.
Final functional predictions, inferred from the metagenomes,
were created with the script predict_metagenomes.py. When
2http://greengenes.secondgenome.com
3http://picrust.github.com
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necessary, tab-delimited tables were obtained with the script
convert_biom.py.
Predicted metagenomic contents were collapsed at the
three hierarchical KEGG pathway levels4 with the catego-
rize_by_function.py script. Each of these tables was analyzed
statistically in STAMP v2.0.1 (32). Association of KEGG pathways
at the different hierarchical levels with the different grouping vari-
ables were identified by running two-sided Welch’s tests on every
pair of means (two grouping variables) or ANOVA/Tukey Kramer
(post hoc) tests (more than two grouping variables). The FDR cor-
rection was finally applied in all cases and significant differences
in KEGG pathways between groups were only considered below a
p-value of 0.05 and a q-value below 0.2 (34). Data of the KEGG
pathway distributions, at different hierarchical levels, were plotted
with the script summarize_taxa_through_plots.py.
RESULTS
IMMUNE DIFFERENCES BETWEEN THE PROXIMAL AND DISTAL
HUMAN COLON
We first studied whether there were immune differences between
the proximal and the distal colon. To that end, the IEL profile
from each compartment was characterized for the three recruited
healthy controls. Total IEL were identified by flow cytometry as
CD45+ CD103+ and their numbers were higher in the proximal
4http://www.genome.jp/kegg/pathway.html
colon (Figure 1A). Further analysis revealed that the IEL compart-
ment was constituted of NK-like cells (CD3−Tγδ−) and T-cells
including both classical (CD3+Tγδ−) and Tγδ cells (CD3+Tγδ+)
(36) (Figure 1B). All three controls had higher numbers of classical
T-cells and lower numbers of Tγδ and NK-like cells in the prox-
imal colon. Proportion of CD4/CD8 T-cell subsets revealed that
the latter were higher in the proximal colon from the three studied
controls (Figure 1C). We also studied the spontaneous produc-
tion of soluble IgA elicited by the proximal and distal colon in
basal culture supernatants, which could potentially modulate the
microbiota composition and found that the proximal colon pro-
duced higher levels of IgA (Figure 1D). These results confirm the
presence of immune differences between the proximal and distal
colon of the three healthy volunteers.
FECAL MICROBIOTA POPULATIONS ARE MODULATED BY THE
PRESENCE OF COLONIC BIOPSIES
When cultured in complete medium, colonic biopsies secrete sol-
uble factors with modulatory effects on immune cells (37–39).
Therefore, host-derived metabolites could also modulate and/or
select the commensal microbiota. Having seen immune differ-
ences between the proximal and distal colon (Figure 1) we next
studied whether colonic microenvironments from the compart-
ments (i) had an effect on the gut microbiota and (ii) if that effect
was differentially elicited by the proximal and distal colon. To
that end, we used a fecal slurry model where a stabilized micro-
biota population was challenged with colonic culture supernatants
C
A
Distal
Proximal
B
Distal
Proximal
D
FIGURE 1 | Immune differences between the proximal and distal
human colon. (A) Intraepithelial lymphocytes (IEL) were identified,
following DTT and EDTA treatment of the colonic biopsies as
CD45+CD103+. (B)Total IELs were subsequently characterized as NK-like
cells (CD3−), T-cells (CD3+), and TγδT-cells (CD3+γδ+). (C)Total T-cells
(CD3+) within IEL were subsequently characterized for CD4 and CD8
expression. Results from (A–C) are representative of three independent
experiments performed with similar results. (D) IgA content was
determined on culture supernatants from paired proximal and distal
colonic biopsies.
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from both proximal and distal colonic culture. As GIT inflamma-
tory responses can modulate the microbiota composition (23),
microbiota conditioning experiments were also performed after
immune challenges of the colonic biopsies with pro-inflammatory
innate cytokines (IL-15) or microbiota antigens (LPS). Negative
controls included basal controls without any stimulation. Stabi-
lized fecal microbiota was mixed with growth media conditioned
by the different biopsies and incubated for 48 h. A fragment
from the 16S rRNA gene was amplified by PCR and sequenced
following a microbiota profiling approach as described in the
material and methods section. This produced 18 microbial pro-
files based on the analysis of the 16S rRNA gene corresponding to
the different experimental conditions [three individuals, two dis-
tal/proximal colon biopsies, three treatments (LPS-, IL-15-treated,
or untreated)], two microbial profiles corresponding to the initial
and final status of the fecal slurry batch, and three extra profiles in
which un-conditioned media wash added to the fecal slurries.
Non-supervised PCA failed to cluster the microbial profiles
according to the treatment (untreated, LPS, IL-15) or according
to the biopsy location (proximal vs. distal colon). However, all
microbiotas that were not exposed to colonic microenviroments
[samples coming from the initial and final untreated fecal slurry
batch (t = 0, t = 48) and those where only culture media had been
added during incubation (t = 48)] clustered apart from the oth-
ers where the biopsy supernatant had been present (Figure 2A).
The same clustering was observed when metagenomic functional-
ity was inferred from the metagenomes through PICRUSt pipeline
(Figure 2B). This clustering was in agreement with the normal-
ized microbiota composition, calculated in percentages at different
taxonomic levels, which was different from microbiotas where the
biopsy supernatant was present, compared with those where it was
absent (Figure S1 in Supplementary Material).
When metagenomic data were clustered according to the pres-
ence or absence of a conditioned biopsy culture supernatant on the
fecal slurry, an increase on the alpha diversity was noticed in the
presence of the biopsy supernatant, whenever the index used was
taking into account species richness (Chao 1, Observed Species) or
evenness (Shannon) (no clear differences were found using Simp-
son index) (Figure 3). Species richness and evenness are two main
components of species diversity. Whereas species richness is the
number of species present in a sample, species evenness refers to
the relative abundance of species.
COMPOUNDS RELEASED BY THE COLONIC BIOPSIES AFFECT SPECIFIC
FECAL MICROBIOTA POPULATIONS
A more detailed analysis of the microbial groups showing changes
in their populations, as affected by the presence or absence of host
secreted compounds, revealed interesting trends in some micro-
bial taxa (Table S1 in Supplementary Material). The Family Pre-
votellaceae (q < 0.12), Enterococcaceae (q < 0.08) and an unclas-
sified Family belonging to the Bacteroidales Order (q < 0.09)
showed moderate increases in the biopsy group. On the con-
trary, an unclassified family belonging to the β-Proteobacteria
class showed lower relative abundance (q < 2E-04) when the
biopsy-released compounds were present in the fecal slurry
batch. Remarkably, several groups of microorganisms were only
detectable in the presence of the biopsy supernatants (in at
least the 50% of the samples). This included the Class TM7-3
(q < 0.03), the families Methanobacteriaceae (q < 0.05), Victival-
laceae (q < 0.04), Actinomycetaceae (q < 0.18), Turicibacteraceae
(q < 0.11), and Eubacteriaceae (q < 0.08), as well as an unclassified
family belonging to the Order Lactobacillales (q < 0.11).
Using the same approach, we studied the effect of the biopsy
supernatant on microbiota functionality by inferring information
on relative KEGG pathway abundances using the PICRUSt soft-
ware, as described in the material and methods section (Table
S2 in Supplementary Material). When focused on the KEGG
level #3, three pathways showed a statistically significant decrease
in the presence of the biopsy. These pathways were Bacterial
Chemotaxis (q < 1.87E-06), Two-component System (q < 0.01)
FIGURE 2 | Principal analysis component plots obtained using the total
microbial population diversity (A) or the relative metabolic pathway
abundances [(B), KEGG pathways] after functional inference through
PICRUSt. Axes represent the two linear variables containing the higher
amount of variability. Open circles and closed squares represent samples
were biopsia supernatants were absent or present, respectively.
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FIGURE 3 | Different alpha diversity indices in the samples were the
colonic biopsia supernatants were absent (dark gray, basal) or present
(light gray, biopsia). Bars represent the mean±SD (*p <0.05;
***p <0.001).
and Glycerophospholipid Metabolism (q < 2.11E-06). On the
contrary, several pathways showed significant increases, such
as streptomycin biosynthesis (q < 4.56E-09), starch and sucrose
metabolism (q < 0.17), ether lipid metabolism (q < 0.12), and
fatty acid metabolism (q < 2E-03).
CYTOKINE LEVELS DID NOT EXPLAIN THE OBSERVED DIFFERENCES IN
MICROBIOTA COMPOSITION
The human colon produced soluble factors, which modulated
both the fecal microbiota composition and its functionality in
terms of KEGG pathway abundance as revealed by the fecal slur-
ries batch experiments. However, there was no differential effect
on microbiota composition elicited by the proximal or the distal
colon, either in resting conditions or after IL-15 or LPS immune
challenges. As human intestinal biopsies secrete several soluble
immunomodulatory factors (37–39), we next determined the con-
centration of several cytokines and adipokines in the culture
supernatants to correlate their concentrations with their observed
effects on the microbiota. There was a high degree of inter-donor
variability in terms of soluble cytokines concentration (Table 1),
with the proximal colon secreting higher amounts of soluble IL-23,
IL-27, and leptin (Figure S2 in Supplementary Material). Follow-
ing culture, IL-15 in vitro challenge did not have any effect on the
production of soluble immune mediators, although LPS increased
the production of several cytokines (Figure S2 in Supplementary
Material). Nevertheless, none of the determined soluble mediators
correlated with the changes elicited on the microbiota composi-
tion and/or functionality after conditioning. Further analysis did
not find a correlation between the observed microbiota modula-
tion by the biopsy supernatants and either their IgA content or
the IEL profile of the samples. Therefore, despite the fact that
the human colonic microenvironment has the capacity to mod-
ulate the microbiota composition via soluble factors, such effect
does not seem to be elicited by any of the measured immune
mediators.
DISCUSSION
Latest research on microbe/host crosstalk has been focused on the
modulation of host processes by the intestinal microbiota through
soluble metabolites (20–22, 40) in the framework of intestinal
disorders (5–8) both in humans and animal models (41). The
results presented in this paper show that such dialog is recipro-
cal, as soluble compounds released by the host also modulated the
composition and functionality of a stable fecal population even
resulting in the detection of otherwise undetectable components.
Despite human proximal and distal colon having different prop-
erties (24–28), they did not elicit any differential effect on the
microbiota composition/functionality, either in basal conditions
or after an innate (IL-15) or microbiota-derived (LPS) immune
challenge. On the contrary, our findings confirmed that the human
colon secretes soluble factors with the ability to modulate the com-
position and functionality of a stable fecal microbiota although the
induced changes did not correlate with any of the many soluble
mediators identified in the supernatants.
When cultured in complete medium, GIT biopsies secrete sev-
eral soluble factors with immunomodulatory effects on immune
cells (2, 37, 39). A limitation of our approach is that in this case
necrotic factors can be release in the media, as the epithelia prefer
to be cultivated with one side exposed to the air. We have used this
model to study whether such colonic-produced soluble factors had
any differential effect on a gut microbiota, via a fecal slurry batch
model (42). Although we considered colonic microenvironments
from the proximal and the distal colon, both in resting condi-
tions and after immune challenges (IL-15 or LPS), the only factor,
which allowed us to group the results, was the presence/absence
of the human colonic microenvironments. Such findings suggest
that the changes induced in the microbiota were independent of
the complete medium components but, on the contrary, elicited by
colonic-derived soluble factors. The presence of the colonic super-
natants resulted in the detection of some groups otherwise unde-
tectable, such as the family Methanobacteriaceae. Members of this
family, belonging to the Archaea Domain, are mainly represented
by Methanobrevibacter smithii (43). This is one of the most abun-
dant species in the human GIT, and it is known that its detection is
strongly underestimated in 16S rRNA gene profiling approaches,
both as result of limits in the technique and in the cell-wall compo-
sition of Archaea (29, 44). These results were in agreement with the
relative metabolic pathway abundances inferred using PICRUSt
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Table 1 | Cytokine levels on the biopsy supernatants.
Distal colon Proximal colon
Basal IL-15 LPS Basal IL-15 LPS
IL-6 146.4±116.2 46.7±34.7 280.1±225.8 115.2±90.7 349.5±282.0 153.0±117.5
IL-22 537.0±418.6 6270.7±322.6 1293.2±742.7 487.5±394.8 1424.2±1029.1 858.6±556.7
IL-9 10.9±7.9 6.2±4.1 30.3±23.7 8.9±6.3 28.6±22.4 15.9±12.0
IL-10 142.8±114.2 93.6±65.9 313.2±253.4 114.6±91.2 396.6±321.4 212.7±171.3
IL-27 51.1±17.1 75.7±18.8 73.9±24.4 133.9±91.6 137.0±102.1 103.8±42.0
IL-2 132.4±107.7 93.1±75.7 265.8±216.7 143.3±90.0 348.1±283.4 204.5±166.7
IL-17A 65.7±52.9 41.9±31.1 130.58±105.8 54.9±47.7 143.9±113.5 106.3±74.1
IFNg 124.6±99.0 84.3±66.0 290.7±234.6 101.2±79.9 329.7±266.4 206.7±166.0
IL-12(p70) 131.4±95.2 137.5±67.8 228.8±178.0 182.4±143.8 388.6±302.9 220.2±143.9
Leptin 254.0±79.7 318.6±65.5 299.9±94.0 500.2±322.7 505.8±315.4 386.7±132.1
TNF alpha 81.4±64.0 51.3±39.3 161.7±125.7 63.6±49.4 216.6±174.3 69.3±54.1
IL-1beta 71.9±57.2 64.8±51.4 241.6±195.8 88.5±69.9 246.8±200.1 154.3±124.5
IL-5 113.9±92.3 83.3±67.4 261.9±201.3 124.0±100.6 302.1±246.0 223.7±182.0
IL-4 75.4±58.8 66.0±52.9 232.4±185.3 85.5±66.9 298.4±235.0 227.5±177.3
IL-13 69.1±52.1 45.8±35.3 205.1±159.7 80.7±64.7 304.4±248.2 168.1±130.2
IL-23 218.1±61.6 345.9±66.7 178.5±41.5 515.6±335.8 429.9±287.4 383.0±160.5
and KEGG. Therefore, increases in Methanobacteriaceae can be
correlated with the ether lipid metabolism, a pathway involved in
the biosynthesis of ether-type polar lipids in Archaea (45). On the
contrary, increases in Clostridiales can be linked with the starch
and sucrose metabolism, as members of this group are well known
by their saccharolytic ability (46).
Nevertheless, we cannot exclude the possibility that the soluble
compounds with capacity to modulate the microbiota composi-
tion and function in our fecal slurry model are not host-derived.
Indeed, it might be possible that the soluble are from bacterial
origin, more concisely those isolated together with the biopsy.
In this sense, it is known that extracellular compounds secreted
by bacteria to the surrounding milieu, such as extracellular pro-
teins/peptides, exopolysaccharides, lipoteichoic acids, or short
chain fatty acids are able to modify the immune host response
(40). However, our results strongly suggest that modifications on
microbiota profiles are co-culture dependent, and therefore a mol-
ecule/molecules secreted by the host mucosa could be affecting the
relative abundances of the gut microbe populations.
Traditional approaches aiming to modulate GIT microbiota
included the use of antibiotics and/or pre/pro/synbiotics combi-
nations which although effective to some extent, often showed
short-term success (10). Fecal transplants, on the contrary, are
being revealed as a promising tool to modulate the GIT micro-
biota (11–14). Nevertheless, there is variability in the outcome of
fecal transplants, as they are not effective in all the patients, which
in part is due to the stability of the resident human microbiota
(15). The human colon secreted soluble factors able to modu-
late a stabilized fecal microbiota. Major individual, location, or
challenge effects were ruled out since the modulation was elicited
irrespective of the donor, sample location (proximal/distal colon),
or immune status (basal/challenge). This is in agreement with
other immune effectors secreted constitutively by the human host
such as breast-milk IgA (47).
Despite immune differences between the proximal and the dis-
tal colon (Figure 1), they did not induce any differential effect
on microbiota composition. However, both ecological niches are
quite similar, so we cannot exclude a differential effect elicited
by other gut compartments (e.g., terminal ileum, duodenum. . .).
Also, all the colon biopsies used in this work were obtained from
healthy adults without known autoimmune diseases, malignancies
or any sign of inflammatory disorders. However, the effect of the
diet and/or ongoing inflammatory processes (even with no clin-
ical manifestations) cannot be discounted from having a role on
the microbial modulation. For instance, higher levels of the fami-
lies Prevotellaceae and Unclassified Bacteroidaceae, both belonging
to the phylum Bacteroidetes, were measured in those fecal slurry
batches where the biopsy supernatants were present. Increases in
Bacteroidetes numbers were observed in other gut-related diseases
such as, for instance, Type-2 Diabetes or Crohn’s Disease (48, 49),
and also in a lean compared with an obese population (50). More-
over, lower Bacteroidetes numbers in cesarean-delivered infants,
has been associated to an increased risk of developing allergic dis-
ease through a reduced Th1 response during the first two years
of life (51). As the tissue microenvironment in patients suffering
from IBD (or other GIT diseases) is different from that in healthy
controls (2, 37), and also dependent on the diet (52), we can-
not exclude the possibility that host-derived soluble factors, which
modulate the GIT microbiota may be altered or even masked by
ongoing pro-inflammatory responses in these patients.
In summary, we have shown that the human colon has the
capacity to modulate the composition of a stabilized fecal micro-
bial population via host-derived soluble factors. Patients with GIT
diseases, including IBD (53), irritable bowel syndrome (IBS) (54),
celiac disease (55), or type-1 diabetes (56) have altered microbiota
composition thought to be a consequence of the immune response.
Moreover, chronic inflammation in the gut such as in the frame-
work of IBD could be a risk for colorectal cancer. As the host has
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the capacity to modulate the microbiota, it could provide a differ-
ential ecological niche and/or selective pressure on the microbiota
via soluble factors which could be responsible (at least partially) for
selecting the altered microbiota observed in such patients. Future
studies should result in identification of such factors, but should
also consider larger cohorts of both controls and patients to study
any differential effects of age, diet, sampled tissue and/or presence
of disease on modulating the microbiota. Factors produced in the
intestinal environment – by either the host or the microbiota –
could also be considered in those strategies aimed at modulating
the microbiota composition. For instance, production of the mol-
ecule 2-aminoacetophenone, which is secreted by Pseudomonas
aeruginosa, promotes bacterial intestinal colonization of model
organisms by various means (57). Further research will assess if
host or microbiota-derived soluble factors differ in those patients
reacting to microbiota modulation (e.g., fecal transplant).
ACKNOWLEDGMENTS
BS and AH were recipients of a Ramón y Cajal postdoctoral
contract and a FPI grant, respectively, from the Spanish Min-
istry of Economy and Competitiveness. The authors gratefully
acknowledge the support of the Biotechnology and Biological Sci-
ences Research Council (BBSRC). This research was funded by the
BBSRC Institute Strategic Programme for Gut Health and Food
Safety BB/J004529/1. This research was also funded by Grants
AGL2010-14952 and AGL2013-44039-R from the Spanish “Plan
Estatal de I+D+ i,” and by Grant EM2014/046 from the “Plan
galego de investigación, innovación e crecemento 2011-2015.”
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://journal.frontiersin.org/article/10.3389/fonc.2015.00086/
abstract
Figure S1 | Microbial composition of the different samples used in this
study at several taxonomic levels, represented as the relative abundances
(%).
Figure S2 | Differential production of cytokines in left vs. right colon (Slide
#1), or with the samples grouped by treatment (Slides #2-9; 1: Basal, 2:
IL-15 or 3: LPS).
Table S1 | Microbial groups showing statistical changes after grouping the
samples using the absence (group 0) or presence (group 1) of biopsia
supernatant in the fecal cultures.
Table S2 | KEGG functions showing statistical changes after grouping the
samples using the absence (group 0) or presence (group 1) of biopsia
supernatant in the fecal cultures.
REFERENCES
1. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens.
Nat Rev Immunol (2003) 3(4):331–41. doi:10.1038/nri1057
2. Bernardo D, Garrote JA, Allegretti Y, Leon A, Gomez E, Bermejo-Martin JF,
et al. Higher constitutive IL15R alpha expression and lower IL-15 response
threshold in coeliac disease patients. Clin Exp Immunol (2008) 154(1):64–73.
doi:10.1111/j.1365-2249.2008.03743.x
3. Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y,
et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes
intestinal homeostasis. Science (2014) 343(6178):1249288. doi:10.1126/science.
1249288
4. El Aidy S, van Baarlen P, Derrien M, Lindenbergh-Kortleve DJ, Hooiveld G, Lev-
enez F, et al. Temporal and spatial interplay of microbiota and intestinal mucosa
drive establishment of immune homeostasis in conventionalized mice. Mucosal
Immunol (2012) 5(5):567–79. doi:10.1038/mi.2012.32
5. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the
gut. Nat Rev Gastroenterol Hepatol (2011) 8(9):523–31. doi:10.1038/nrgastro.
2011.133
6. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat
Rev Gastroenterol Hepatol (2012) 9(10):599–608. doi:10.1038/nrgastro.2012.152
7. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al.
Host-gut microbiota metabolic interactions. Science (2012) 336(6086):1262–7.
doi:10.1126/science.1223813
8. Shanahan F. The gut microbiota in 2011 translating the microbiota to medicine.
Nat Rev Gastroenterol Hepatol (2012) 9(2):72–4. doi:10.1038/nrgastro.2011.250
9. van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist
L, et al. EURECCA colorectal: multidisciplinary management: European con-
sensus conference colon & rectum. Eur J Cancer (2014) 50(1):1.e1–1.e34.
doi:10.1016/j.ejca.2013.06.048
10. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in
intestinal health and disease. Nat Rev Gastroenterol Hepatol (2010) 7(9):503–14.
doi:10.1038/nrgastro.2010.117
11. Relman DA. Restoration of the gut microbial habitat as a disease therapy. Nat
Biotechnol (2013) 31(1):35–7. doi:10.1038/nbt.2475
12. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al.
Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J
Med (2013) 368(5):407–15. doi:10.1056/NEJMoa1205037
13. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JFWM,
et al. Transfer of intestinal microbiota from lean donors increases insulin
sensitivity in individuals with metabolic syndrome. Gastroenterology (2012)
143(4): 913–6.e7. doi:10.1053/j.gastro.2012.06.031
14. Borody TJ, Campbell J. Fecal microbiota transplantation techniques, applica-
tions, and issues. Gastroenterol Clin North Am (2012) 41(4):781–803. doi:10.
1016/j.gtc.2012.08.008
15. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman
AL, et al. The long-term stability of the human gut microbiota. Science (2013)
341(6141):1237439. doi:10.1126/science.1237439
16. Qin JJ, Li RQ, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human
gut microbial gene catalogue established by metagenomic sequencing. Nature
(2010) 464(7285):59–65. doi:10.1038/nature08821
17. Cummings JH, Macfarlane GT. The control and consequences of bacter-
ial fermentation in the human colon. J Appl Bacteriol (1991) 70(6):443–59.
doi:10.1111/j.1365-2672.1991.tb02739.x
18. Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape
the nutrient environment of the mammalian intestine. Annu Rev Nutr (2002)
22:283–307. doi:10.1146/annurev.nutr.22.011602.092259
19. Zhang ZG, Geng JW, Tang XD, Fan H, Xu JC, Wen XJ, et al. Spatial heterogeneity
and co-occurrence patterns of human mucosal-associated intestinal microbiota.
ISME J (2014) 8(4):881–93. doi:10.1038/ismej.2013.185
20. Al-Hassi HO, Mann ER, Sanchez B, English NR, Peake STC, Landy J, et al. Altered
human gut dendritic cell properties in ulcerative colitis are reversed by Lac-
tobacillus plantarum extracellular encrypted peptide STp. Mol Nutr Food Res
(2014) 58(5):1132–43. doi:10.1002/mnfr.201300596
21. Bernardo D, Sanchez B, Al-Hassi HO, Mann ER, Urdaci MC, Knight SC, et al.
Microbiota/host crosstalk biomarkers: regulatory response of human intestinal
dendritic cells exposed to Lactobacillus extracellular encrypted peptide. PLoS
One (2012) 7(5):e36262. doi:10.1371/journal.pone.0036262
22. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al.
The microbial metabolites, short-chain fatty acids, regulate colonic T-reg cell
homeostasis. Science (2013) 341(6145):569–73. doi:10.1126/science.1241165
23. Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ,
et al. Intestinal inflammation targets cancer-inducing activity of the microbiota.
Science (2012) 338(6103):120–3. doi:10.1126/science.1224820
24. Seitz HK, Egerer G, Oneta C, Kramer S, Sieg A, Klee F, et al. Alcohol dehy-
drogenase in the human colon and rectum. Digestion (1996) 57(2):105–8.
doi:10.1159/000201322
25. Simren M, Stotzer PO, Sjovall H, Abrahamsson H, Bjornsson ES. Abnormal
levels of neuropeptide Y and peptide YY in the colon in irritable bowel syn-
drome. Eur J Gastroenterol Hepatol (2003) 15(1):55–62. doi:10.1097/00042737-
200301000-00010
Frontiers in Oncology | Cancer Endocrinology April 2015 | Volume 5 | Article 86 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hevia et al. Host-induced microbiota modulation
26. Eriksson K, Quiding-Jarbrink M, Osek J, Nordstrom I, Hjulstrom M, Holmgren
J, et al. Anatomic segmentation of the intestinal immune response in nonhu-
man primates: differential distribution of B cells after oral and rectal immuniza-
tions to sites defined by their source of vascularization. Infect Immun (1999)
67(11):6210–2.
27. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, et al.
Distinguishing right from left colon by the pattern of gene expression. Cancer
Epidemiol Biomarkers Prev (2003) 12(8):755–62.
28. Kaz AM, Wong CJ, Dzieciatkowski S, Luo YX, Schoen RE, Grady WM. Patterns
of DNA methylation in the normal colon vary by anatomical location, gender,
and age. Epigenetics (2014) 9(4):492–502. doi:10.4161/epi.27650
29. Milani C, Hevia A, Foroni E, Duranti S, Turroni F, Lugli GA, et al. Assessing
the fecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis
protocol. PLoS One (2013) 8(7):e68739. doi:10.1371/journal.pone.0068739
30. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK,
et al. QIIME allows analysis of high-throughput community sequencing data.
Nat Methods (2010) 7(5):335–6. doi:10.1038/nmeth.f.303
31. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioin-
formatics (2010) 26(19):2460–1. doi:10.1093/bioinformatics/btq461
32. Parks DH, Beiko RG. Identifying biologically relevant differences between
metagenomic communities. Bioinformatics (2010) 26(6):715–21. doi:10.1093/
bioinformatics/btq041
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate – a practical and
powerful approach to multiple testing. J R Stat Soc Series B Methodol (1995)
57(1):289–300.
34. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL,Ward DV, et al. Dysfunc-
tion of the intestinal microbiome in inflammatory bowel disease and treatment.
Genome Biol (2012) 13(9):R79. doi:10.1186/gb-2012-13-9-r79
35. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA,
et al. Predictive functional profiling of microbial communities using 16S rRNA
marker gene sequences. Nat Biotechnol (2013) 31(9):814–21. doi:10.1038/nbt.
2676
36. Eiras P, Leon F, Camarero C, Lombardia M, Roldan E, Bootello A, et al. Intestinal
intraepithelial lymphocytes contain a CD3(-) CD7(+) subset expressing natural
killer markers and a singular pattern of adhesion molecules. Scand J Immunol
(2000) 52(1):1–6. doi:10.1046/j.1365-3083.2000.00761.x
37. Al-Hassi HO, Bernardo D, Murugananthan AU, Mann ER, English NR, Jones
A, et al. A mechanistic role for leptin in human dendritic cell migration: differ-
ences between ileum and colon in health and Crohn’s disease. Mucosal Immunol
(2013) 6(4):751–61. doi:10.1038/mi.2012.113
38. Bernardo D, Vallejo-Diez S, Mann ER, Al-Hassi HO, Martinez-Abad B, Mon-
talvillo E, et al. IL-6 promotes immune responses in human ulcerative colitis
and induces a skin-homing phenotype in the dendritic cells and T cells they
stimulate. Eur J Immunol (2012) 42(5):1337–53. doi:10.1002/eji.201142327
39. Mann ER, Bernardo D, Al-Hassi HO, English NR, Clark SK, McCarthy NE, et al.
Human gut-specific homeostatic dendritic cells are generated from blood pre-
cursors by the gut microenvironment. Inflamm Bowel Dis (2012) 18(7):1275–86.
doi:10.1002/ibd.21893
40. Ruiz L, Hevia A, Bernardo D, Margolles A, Sanchez B. Extracellular mol-
ecular effectors mediating probiotic attributes. FEMS Microbiol Lett (2014)
359(1):1–11. doi:10.1111/1574-6968.12576
41. Cani PD. Metabolism in 2013 the gut microbiota manages host metabolism. Nat
Rev Endocrinol (2014) 10(2):74–6. doi:10.1038/nrendo.2013.240
42. Salazar N, Gueimonde M, Hernandez-Barranco AM, Ruas-Madiedo P, Reyes-
Gavilan CGDL. Exopolysaccharides produced by intestinal Bifidobacterium
strains act as fermentable substrates for human intestinal bacteria. Appl Environ
Microbiol (2008) 74(15):4737–45. doi:10.1128/AEM.00325-08
43. Samuel BS, Hansen EE, Manchester JK, Coutinho PM, Henrissat B, Fulton R,
et al. Genomic and metabolic adaptations of Methanobrevibacter smithii to the
human gut. Proc Natl Acad Sci U S A (2007) 104(25):10643–8. doi:10.1073/pnas.
0704189104
44. Walker AW, Duncan SH, Louis P, Flint HJ. Phylogeny, culturing, and metage-
nomics of the human gut microbiota. Trends Microbiol (2014) 22(5):267–74.
doi:10.1016/j.tim.2014.03.001
45. Koga Y, Morii H. Biosynthesis of ether-type polar lipids in archaea and evo-
lutionary considerations. Microbiol Mol Biol Rev (2007) 71(1):97–120. doi:10.
1128/MMBR.00033-06
46. Hemme CL, Mouttaki H, Lee YJ, Zhang GX, Goodwin L, Lucas S, et al. Sequenc-
ing of multiple clostridial genomes related to biomass conversion and biofuel
production. J Bacteriol (2010) 192(24):6494–6. doi:10.1128/JB.01064-10
47. Rogier EW, Frantz AL, Bruno MEC, Wedlund L, Cohen DA, Stromberg AJ, et al.
Secretory antibodies in breast milk promote long-term intestinal homeostasis
by regulating the gut microbiota and host gene expression. Proc Natl Acad Sci U
S A (2014) 111(8):3074–9. doi:10.1073/pnas.1315792111
48. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen
BK, et al. Gut microbiota in human adults with type 2 diabetes differs from
non-diabetic adults. PLoS One (2010) 5(2):e9085. doi:10.1371/journal.pone.
0009085
49. Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-
recognition receptors in Crohn’s disease. Nat Rev Gastroenterol Hepatol (2011)
8(3):152–68. doi:10.1038/nrgastro.2011.3
50. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An
obesity-associated gut microbiome with increased capacity for energy harvest.
Nature (2006) 444(7122):1027–31. doi:10.1038/nature05414
51. Jakobsson HE, Abrahamsson TR, Jenmalm MC, Harris K, Quince C, Jernberg
C, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation
and reduced Th1 responses in infants delivered by caesarean section. Gut (2014)
63(4):559–66. doi:10.1136/gutjnl-2012-303249
52. Chewapreecha C.Your gut microbiota are what you eat. Nat Rev Microbiol (2014)
12(1):8. doi:10.1038/nrmicro3186
53. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Jarnerot G, Engstrand L, et al.
Twin studies reveal specific imbalances in the mucosa-associated microbiota
of patients with ileal Crohn’s disease. Inflamm Bowel Dis (2009) 15(5):653–60.
doi:10.1002/ibd.20783
54. Clarke G, Quigley EMM, Cryan JF, Dinan TG. Irritable bowel syndrome:
towards biomarker identification. Trends Mol Med (2009) 15(10):478–89.
doi:10.1016/j.molmed.2009.08.001
55. Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Specific duode-
nal and faecal bacterial groups associated with paediatric coeliac disease. J Clin
Pathol (2009) 62(3):264–9. doi:10.1136/jcp.2008.061366
56. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al.
Innate immunity and intestinal microbiota in the development of type 1 dia-
betes. Nature (2008) 455(7216):1109–U10. doi:10.1038/nature07336
57. Kapsetaki SE, Tzelepis I, Avgousti K, Livadaras I, Garantonakis N, Varikou K,
et al. The bacterial metabolite 2-aminoacetophenone promotes association of
pathogenic bacteria with flies. Nat Commun (2014) 5:4401. doi:10.1038/
ncomms5401
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 05 December 2014; paper pending published: 19 March 2015; accepted: 23
March 2015; published online: 13 April 2015.
Citation: Hevia A, Bernardo D, Montalvillo E, Al-Hassi HO, Fernández-Salazar L,
Garrote JA, Milani C, Ventura M, Arranz E, Knight SC, Margolles A and Sánchez
B (2015) Human colon-derived soluble factors modulate gut microbiota composition.
Front. Oncol. 5:86. doi: 10.3389/fonc.2015.00086
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers
in Oncology.
Copyright © 2015 Hevia, Bernardo, Montalvillo, Al-Hassi, Fernández-Salazar, Gar-
rote, Milani, Ventura, Arranz, Knight , Margolles and Sánchez. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org April 2015 | Volume 5 | Article 86 | 9
